IP Library Granted Patent US 9,381,242
Granted Patent B2
US 9,381,242 · App. 14/004,308 · Granted Jul 5, 2016

Adjuvant composition containing citrulline

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,242
App. No.
14/004,308
Granted
Jul 5, 2016
Kind
B2
Abstract

A novel adjuvant composition is provided that is excellent in safety and convenience as compared to the conventional adjuvant such as Alum. An adjuvant composition comprising citrullines, which are water soluble substance present in the living body, and/or a salt thereof; a vaccine composition comprising said adjuvant composition and an antigen; a process for preparing said adjuvant composition and said vaccine composition; and a method for administering said adjuvant composition and said vaccine composition are provided.

Claims (20)

1. A vaccine composition comprising an adjuvant composition comprising an adjuvant effective amount of citrulline and a hemagglutinin antigen from influenza virus, wherein the adjuvant effective amount of citrulline ranges from 1 mg/mL to 50 mg/mL.

2. The vaccine composition according to claim 1 , wherein the citrulline is at least one member selected from the group consisting of L-citrulline, D-citrulline, L-thiocitrulline, L-thiohomocitrulline, S-methyl-L-thio-citrulline and S-ethyl-L-thiocitrulline.

3. The vaccine composition according to claim 2 , wherein the citrulline is L-citrulline or D-citrulline.

4. The vaccine composition according to claim 1 , comprising 5 mg/mL to 45 mg/mL of the citrulline.

5. The vaccine composition according to claim 1 , further comprising an antioxidant.

6. The vaccine composition according to claim 5 , wherein the antioxidant is ascorbic acid.

7. The vaccine composition according to claim 5 , wherein a weight ratio of the citrulline to the antioxidant is 1:2 to 2:1.

8. The vaccine composition according to claim 5 , comprising 1 to 10 mg/mL of the antioxidant.

9. The vaccine composition according to claim 1 , wherein a weight ratio of the antigen to the citrulline is 1:N wherein N is 100 or more.

10. The vaccine composition according to claim 9 , wherein a weight ratio of the antigen to the citrulline is 1:N wherein N is 300 or more.

11. The vaccine composition according to claim 10 , wherein a weight ratio of the antigen to the citrulline is 1:N wherein N is 3000 or more.

12. A process for preparing the vaccine according to claim 1 , comprising adding a citrulline to a hemagglutinin antigen from influenza virus, wherein the amount of citrulline in said vaccine ranges from 1 mg/mL to 50 mg/mL.

13. The process according to claim 12 , wherein the citrulline is at least one member selected from the group consisting of L-citrulline, D-citrulline, L-thiocitrulline, L-thiohomocitrulline, S-methyl-L-thio-citrulline and S-ethyl-L-thiocitrulline.

14. The process according to claim 13 , wherein the citrulline is L-citrulline or D-citrulline.

15. The process according to claim 12 , wherein a weight ratio of the antigen to the citrulline is 1:N wherein N is 100 or more.

16. The process according to claim 15 , wherein a weight ratio of the antigen to the citrulline is 1:N wherein N is 300 or more.

17. The process according to claim 12 , further comprising adding an antioxidant to the vaccine.

18. The process according to claim 17 , wherein the antioxidant is ascorbic acid.

19. The process according to claim 17 , wherein the citrulline and the antioxidant are in a weight ratio of 1:2 to 2:1, and are added to the hemagglutinin antigen.

20. The process according to claim 17 , wherein the antioxidant is added at a concentration of 1 to 10 mg/mL.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2013
From: NOZAKI, CHIKATERU; KAMINAKA, KAZUYOSHI; MATSUDA, JUNICHI
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 031211/0233 →